Pharmacotherapy of obesity

Experimental and Clinical Endocrinology and Diabetes

Volumn 114, Issue 9, 2006, Pages 475-484

  Hofbauer, K C ^a   Nicholson, J R ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Adipose tissue; Appetite; Drugs; Energy balance; Metabolism

Indexed keywords

6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID; AMFEPRAMONE; ANTIOBESITY AGENT; AOD 9604; APD 356; ATL 962; CEFAMADAR; CLONIDINE; CP 945598; DEXFENFLURAMINE; DOPA; FENFLURAMINE; GW 856464; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MELANOCORTIN RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; PEPTIDE YY; PHENTERMINE RESIN; PHENYLPROPANOLAMINE; PLACEBO; PRAMLINTIDE; RECATOL; RECOMBINANT LEPTIN; RIMONABANT; SIBUTRAMINE; SOLABEGRON; SPIRONOLACTONE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ANXIETY DISORDER; BODY WEIGHT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIET THERAPY; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENERGY BALANCE; EXERCISE; FECES INCONTINENCE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERKALEMIA; LIFESTYLE; META ANALYSIS; MOOD DISORDER; NAUSEA; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; STEATORRHEA; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTI-OBESITY AGENTS; CLINICAL TRIALS; CYCLOBUTANES; DRUG DESIGN; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; LACTONES; LIFE STYLE; MODELS, BIOLOGICAL; OBESITY; PIPERIDINES; PYRAZOLES; TECHNOLOGY, PHARMACEUTICAL;

EID: 33845294036     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924241     Document Type: Review

References (84)

1. Ahima RS, Osei SY. Leptin signaling. Physiol Behav 2004; 81: 223-241
2. Argyropoulos G, Harper ME. Uncoupling proteins and thermoregulation. J Appl Physiol 2002; 92: 2187-2198
3. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994-1003
4. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005; 45: 1035-1041
5. Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science 2005; 307: 1909-1914
6. Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T, Ferreira M, Tang V, McGovern RA, Kenny CD, Christiansen LM, Edelstein E, Choi B, Boss O, Aschkenasi C, Zhang CY, Mountjoy K, Kishi T, Elmquist JK, Lowell BB. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 2005; 123: 493-505
7. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertaler L, Mackie K, Rudd MA, Bukoski RD, Kunos G. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004; 110: 1996-2002
8. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-948
9. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12: 1197-1211
10. Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients-sibutramine and blood pressure. Clin Auton Res 2005; 15: 200-206
11. Boggiano MM, Chandler PC, Oswald KD, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Schindler M, Arndt K, Rudolf K, Mark M, Schoelch C, Joost HG, Klaus S, Thone-Reineke C, Benoit SC, Seeley RJ, Beck-Sickinger AG, Koglin N, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Ortmann S, Castaneda TR, Tschop M. PYY3-36 as an antiobesity drug target. Obes Rev 2005; 6: 307-322
12. Boss O, Bergenhem N. Adipose targets for obesity drug development. Expert Opin Ther Targets 2006; 10: 119-134
13. Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPAR γ-agonist-mediated improvements in hepatic insulin sensitivity? Int J Obes (Lond) 2005; 29; S17-S23
14. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20: 805-875
15. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638
16. Chan CB, Saleh MC, Koshkin V, Wheeler MB. Uncoupling protein 2 and islet function. Diabetes 2004; 53: S136-S142
17. Chiesi M, Huppertz C, Hofbauer KG. Pharmacotherapy of obesity: targets and perspectives. Trends Pharmacol Sci 2001; 22: 247-254
18. Collins S, Cao W, Robidoux J. Learning new tricks from old dogs: beta-adrenergic receptors teach new lessons on firing up adipose tissue metabolism. Mol Endocrinol 2004; 18: 2123-2131
19. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci 2005; 8: 571-578
20. Cummings DE, Foster-Schubert KE, Overduin J. Ghrelin and energy balance: focus on current controversies. Curr Drug Targets 2005; 6: 153-169
21. Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs 2004; 64: 2845-2864
22. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-242
23. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C. Effect of peptide YY(3-36) on food intake in humans. Gastroenterology 2005; 129: 1430-1436
24. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134
25. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-589
26. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal pt-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004; 16: 51-59
27. Dulloo AG. Dietary supplements and herbal preparations. In: Hofbauer KG, Keller U, Boss O (eds). Pharmacotherapy of Obesity. Options and Alternatives. Boca Raton: CRC Press, 2004; 405-419
28. Fishman AP. Aminorex to fen/phen. An epidemic foretold. Circulation 1999; 99: 156-161
29. Flegal KM. Epidemiologic aspects of overweight and obesity in the United States. Physiol Behav 2005; 86: 599-602
30. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350
31. Greenway FL, Heber D. Herbal and alternative approaches to obesity. In: Bray GA, Bouchard C (eds). Handbook of Obesity 2nd edn. New York: Marcel Dekker, Inc., 2004; 329-358
32. Grundy SM, Cleeman JI, Daniels SR, Donate KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735-2752
33. Gura T. Obesity drug pipeline not so fat. Science 2003; 299: 849-852
34. 3-36 produces conditioned taste aversion in mice. Cell Metabolism 2005; 1: 159-168
35. Halford JC. Clinical pharmacotherapy for obesity: current drugs and those in advanced development. Curr Drug Targets 2004; 5: 637-646
36. Harper JA, Dickinson K, Brand MD. Mitochondrial uncoupling as a target for drug development for the treatment of obesity. Obes Rev 2001; 2: 255-265
37. Harper M-E, Dent R, Tesson F, McPherson R. Targeting thermogenesis in the development of antiobesity drugs. In: Hofbauer KG, Keller U, Boss O (eds). Pharmacotherapy of Obesity. Options and alternatives. Boca Raton: CRC Press, 2004; 363-383
38. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209
39. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among us children, adolescents, and adults, 1999-2002. JAMA 2004; 291: 2847-2850
40. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD 9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 2001; 142: 5182-5189
41. Herzog H. Neuropeptide Y and energy homeostasis: insights from y receptor knockout models. Eur J Pharmacol 2003; 480: 21-29
42. Hesselink MK, Mensink M, Schrauwen P. Human uncoupling protein-3 and obesity: an update. Obes Res 2003; 11: 1429-1443
43. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568-1575
44. Hauner H. Orlistat. In: Hofbauer KG, Keller U, Boss O (eds). Pharmacotherapy of Obesity. Options and Alternatives. Boca Raton: CRC Press, 2004; 219-243
45. Juurhnk DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351: 543-551
46. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304
47. Katz DL. Competing dietary claims for weight loss: finding the forest through truculent trees. Annu Rev Public Health 2005; 26: 61-88
48. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
49. Kolanowski J. A risk-benefit assessment of antiobesity drugs. Drug Saf 1999; 20: 119-131
50. Korner J, Aronne LJ. Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab 2004; 89: 2616-2621
51. Kuo JJ, Silva AA, Hall JE. Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function. Hypertension 2003; 41: 768-774
52. Lafontan M. Fat cells: afferent and efferent messages define new approaches to treat obesity. Annu Rev Pharmacol Toxicol 2005; 45: 119-146
53. Lazar MA. How obesity causes diabetes: not a tall tale. Science 2005; 307: 373-375
54. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332: 621-628
55. Levine JA, Lanningham-Foster LM, McCrady SK, Krizan AC, Olson LR, Kane PH, Jensen MD, Clark MM. Interindividual variation in posture allocation: possible role in human obesity. Science 2005; 307: 584-586
56. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546
57. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH, Nguyen NT, Li Z, Mojica WA, Hilton L, Rhodes S, Morton SC, Shekelle PG. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005; 142: 547-559
58. Mashiko S, Ishihara A, Gomori A, Moriya R, Ito M, Iwaasa H, Matsuda M, Feng Y, Shen Z, Marsh DJ, Bednarek MA, MacNeil DJ, Kanatani A. Antiobesity effect of a melanin-concentrating hormone 1 receptor antagonist in diet-induced obese mice. Endocrinology 2005; 146: 3080-3086
59. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3: 35-42
60. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 45-62
61. Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H, Yoshimura A. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 2004; 10: 739-743
62. Moyers SB. Medications as adjunct therapy for weight loss: approved and off-label agents in use. J Am Diet Assoc 2005; 105: 948-959
63. Nawrocki AR, Scherer PE. Keynote review: the adipocyte as a drug discovery target. Drug Discov Today 2005; 10: 1219-1230
64. Nisoli E, Carruba MO. Emerging aspects of pharmacotherapy for obesity and metabolic syndrome. Pharmacol Res 2004; 50: 453-469
65. Nordheim U, Nicholson JR, Dokladny K, Dunant P, Hofbauer KG. Cardiovascular responses to melanocortin 4-receptor stimulation in conscious unrestrained normotensive rats. Peptides 2006; 27: 438-443
66. O'Rahilly S, Yeo GS, Farooqi IS. Melanocortin receptors weigh in. Nat Med 2004; 10: 351-352
67. Park A, Bloom SR. Peptides and obesity: the PYY3-36 story. Regul Pept 2004; 119: 1-2
68. b8 Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147: S163-S171
69. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. An update of the 1997 American Heart Association scientific statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918
70. Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol 2006; 35: 93-99
71. Ryan DH. Sibutramine. In: Hofbauer KG, Keller U, Boss O (eds). Pharmacotherapy of Obesity. Options and Alternatives. Boca Raton: CRC Press, 2004; 245-266
72. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 2004; 53: S233-S238
73. Schwartz MW, Porte D Jr. Diabetes, obesity, and the brain. Science 2005; 307: 375-379
74. Ste Marie L, Luquet S, Cole TB, Palmiter RD. Modulation of neuropeptide y expression in adult mice does not affect feeding. Proc Natl Acad Sci USA 2005; 102: 18632-18637
75. Tsai AG, Wadden TA. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med 2005; 142: 56-66
76. Ueno H, Yamaguchi H, Kangawa K, Nakazato M. Ghrelin. A gastric peptide that regulates food intake and energy homeostasis. Regul Pept 2005; 126: 11-19
77. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the Rio-Europe Study. Lancet 2005; 365: 1389-1397
78. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ. Randomized trial of life-style modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-2120
79. Wagner JA, Hu K, Bauersachs J, Karcher J, Wiesler M, Goparaju SK, Kunos G, Ertl G. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 2001; 38: 2048-2054
80. Wessells H, Blevins JE, Vanderah TW. Melanocortinergic control of penile erection. Peptides 2005; 26: 1972-1977
81. Wolfe BM, Morton JM. Weighing in on bariatric surgery: procedure use, readmission rates, and mortality. JAMA 2005; 294: 1960-1963
82. Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 2006; 12: 62-66
83. Yanagisawa T, Sato T, Yamada H, Sukegawa J, Nunoki K. Selectivity and potency of agonists for the three subtypes of cloned human beta-adrenoceptors expressed in Chinese hamster ovary cells. Tohoku J Exp Med 2000; 192: 181-193
84. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591-602